» Articles » PMID: 22984225

Identification and Functional Characterization of a Novel UDP-glucuronosyltransferase 2A1 Splice Variant: Potential Importance in Tobacco-related Cancer Susceptibility

Overview
Specialty Pharmacology
Date 2012 Sep 18
PMID 22984225
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

UDP-glucuronosyltransferase (UGT) 2A1 is a respiratory and aerodigestive tract-expressing phase II detoxifying enzyme that metabolizes various xenobiotics including polycyclic aromatic hydrocarbons (PAHs). In the present study, a novel exon 3 deletion splice variant was identified for UGT2A1 (UGT2A1Δexon3). As determined by reverse transcription-polymerase chain reaction (PCR), UGT2A1Δexon3 was shown to be expressed in various tissues including lung, trachea, larynx, tonsil, and colon. The ratio of UGT2A1Δexon3/wild-type UGT2A1 expression was highest in colon (0.79 ± 0.08) and lung (0.42 ± 0.12) as determined by real-time PCR; an antibody specific to UGT2A1 showed splice variant protein (UGT2A1_i2) to wild-type protein (UGT2A1_i1) ratios in the range of 0.5 to 0.9 in these tissues. Using ultra-pressure liquid chromatography, we found that homogenates prepared from UGT2A1_i2-overexpressing human embryonic kidney 293 cells exhibited no glucuronidation activity against PAHs, including benzo[a]pyrene-7,8-dihydrodiol (B[a]P-7,8-diol). An inducible in vitro system was created to determine the effect of UGT2A1_i2 expression on UGT2A1_i1 activity. Increasing UGT2A1_i2 levels resulted in a significant (p < 0.01) decrease in the UGT2A1_i1 V(max) against 1-hydroxy (OH)-pyrene, 3-OH-benzo[a]pyrene, and B[a]P-7,8-diol; no significant changes in K(M) were observed for any of the three substrates. Coimmunoprecipitation experiments suggested the formation of UGT2A1_i1 and UGT2A1_i2 hetero-oligomers and UGT2A1_i1 homo-oligomers; coexpression of UGT2A1_i1 or UGT2A1_i2 with other UGT1A or UGT2B enzymes caused no change in UGT1A or UGT2B glucuronidation activity. These data suggest that a novel UGT2A1 splice variant regulates UGT2A1-mediated glucuronidation activity via UGT2A1-specific protein-protein interactions, and expression of this variant could play an important role in the detoxification of carcinogens within target tissues for tobacco carcinogenesis.

Citing Articles

Integrated clinical genomic analysis reveals xenobiotic metabolic genes are downregulated in meningiomas of current smokers.

Khan A, Patel R, McDonald M, Goethe E, English C, Gadot R J Neurooncol. 2023; 163(2):397-405.

PMID: 37318677 DOI: 10.1007/s11060-023-04359-7.


Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites.

Nasrin S, Watson C, Bardhi K, Fort G, Chen G, Lazarus P Drug Metab Dispos. 2021; 49(12):1081-1089.

PMID: 34493601 PMC: 11022890. DOI: 10.1124/dmd.121.000530.


The odorant metabolizing enzyme UGT2A1: Immunolocalization and impact of the modulation of its activity on the olfactory response.

Neiers F, Jarriault D, Menetrier F, Faure P, Briand L, Heydel J PLoS One. 2021; 16(3):e0249029.

PMID: 33765098 PMC: 7993815. DOI: 10.1371/journal.pone.0249029.


Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.

Grant D, Manichaikul A, Alberg A, Bandera E, Barnholtz-Sloan J, Bondy M Cancer Med. 2019; 8(5):2503-2513.

PMID: 31001917 PMC: 6536963. DOI: 10.1002/cam4.1996.


Regulation of UGT2A1 by miR-196a-5p and miR-196b-5p.

Sutliff A, Watson C, Chen G, Lazarus P J Pharmacol Exp Ther. 2019; 369(2):234-243.

PMID: 30850392 PMC: 6439457. DOI: 10.1124/jpet.118.255935.


References
1.
Webb L, Miles K, Auyeung D, Kessler F, Ritter J . Analysis of substrate specificities and tissue expression of rat UDP-glucuronosyltransferases UGT1A7 and UGT1A8. Drug Metab Dispos. 2004; 33(1):77-82. DOI: 10.1124/dmd.104.001321. View

2.
Jones N, Sun D, Freeman W, Lazarus P . Quantification of Hepatic UDP glucuronosyltransferase 1A splice variant expression and correlation of UDP glucuronosyltransferase 1A1 variant expression with glucuronidation activity. J Pharmacol Exp Ther. 2012; 342(3):720-9. PMC: 3422519. DOI: 10.1124/jpet.112.192658. View

3.
Laakkonen L, Finel M . A molecular model of the human UDP-glucuronosyltransferase 1A1, its membrane orientation, and the interactions between different parts of the enzyme. Mol Pharmacol. 2010; 77(6):931-9. DOI: 10.1124/mol.109.063289. View

4.
Wiener D, Fang J, Dossett N, Lazarus P . Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes. Cancer Res. 2004; 64(3):1190-6. DOI: 10.1158/0008-5472.can-03-3219. View

5.
Balliet R, Chen G, Gallagher C, Dellinger R, Sun D, Lazarus P . Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res. 2009; 69(7):2981-9. PMC: 2694132. DOI: 10.1158/0008-5472.CAN-08-4143. View